TACC3 and central nervous system cancer: Erdafitinib (JNJ-42756493) is a potent, orally active small molecule with potent tyrosine kinase inhibitory activity against all 4 FGFR family members.90 A recent study with IDH wild-type glioma showed that erdafitinib potently inhibited the proliferation of glioma cells harboring FGFR3-TACC3 fusions in vitro, and tumor growth in vivo.